 - ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis - - Commercial launch expected in April 2021 - - Kiniksa launches Kiniksa One ConnectTM patient support program - - Conference call and webcast scheduled for 5:30 p.m. EDT today - 